Whittier Trust Co. of Nevada Inc. Acquires 655 Shares of ICON Public Limited (NASDAQ:ICLR)

Whittier Trust Co. of Nevada Inc. increased its holdings in shares of ICON Public Limited (NASDAQ:ICLR) by 128.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,166 shares of the medical research company’s stock after purchasing an additional 655 shares during the period. Whittier Trust Co. of Nevada Inc.’s holdings in ICON Public were worth $245,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ICLR. Natixis Advisors LLC lifted its position in ICON Public by 6.7% during the fourth quarter. Natixis Advisors LLC now owns 177,761 shares of the medical research company’s stock valued at $37,279,000 after acquiring an additional 11,177 shares during the last quarter. Kornitzer Capital Management Inc. KS lifted its position in ICON Public by 40.6% during the fourth quarter. Kornitzer Capital Management Inc. KS now owns 97,102 shares of the medical research company’s stock valued at $20,363,000 after acquiring an additional 28,050 shares during the last quarter. Foyston Gordon & Payne Inc purchased a new stake in ICON Public during the third quarter valued at approximately $11,672,000. Entropy Technologies LP lifted its position in ICON Public by 472.2% during the fourth quarter. Entropy Technologies LP now owns 6,174 shares of the medical research company’s stock valued at $1,295,000 after acquiring an additional 5,095 shares during the last quarter. Finally, Whittier Trust Co. lifted its position in ICON Public by 17.8% during the fourth quarter. Whittier Trust Co. now owns 4,736 shares of the medical research company’s stock valued at $993,000 after acquiring an additional 716 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently commented on ICLR. Royal Bank of Canada reissued an “outperform” rating and set a $263.00 target price on shares of ICON Public in a research report on Wednesday, January 15th. Truist Financial decreased their price target on shares of ICON Public from $284.00 to $262.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Barclays decreased their price target on shares of ICON Public from $275.00 to $240.00 and set an “overweight” rating for the company in a report on Friday, February 21st. Citigroup decreased their price target on shares of ICON Public from $300.00 to $290.00 and set a “buy” rating for the company in a report on Monday, January 6th. Finally, JPMorgan Chase & Co. decreased their price target on shares of ICON Public from $280.00 to $265.00 and set an “overweight” rating for the company in a report on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $272.50.

ICON Public Stock Up 0.5 %

ICLR stock opened at $184.87 on Monday. The firm has a market cap of $14.93 billion, a PE ratio of 19.40, a P/E/G ratio of 1.86 and a beta of 1.21. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.34 and a current ratio of 1.26. The firm’s fifty day moving average is $192.76 and its 200 day moving average is $225.70. ICON Public Limited has a one year low of $174.93 and a one year high of $347.72.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.41 by $0.01. The company had revenue of $2.04 billion for the quarter, compared to analyst estimates of $2.04 billion. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. On average, research analysts forecast that ICON Public Limited will post 13.38 EPS for the current year.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.